Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alirocumab - Regeneron/Sanofi

Drug Profile

Alirocumab - Regeneron/Sanofi

Alternative Names: Anti-PCSK9 monoclonal antibody - Regeneron/Sanofi; Anti-proprotein convertase subtilisin kexin type 9 monoclonal antibody - Regeneron/Sanofi; Praluent; REGN-727; SAR-236553

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antihyperlipidaemics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipoproteinaemia type II

Most Recent Events

  • 20 Mar 2024 Registered for Hyperlipoproteinaemia type II (In adolescents, In children) in Liechtenstein, Norway, Iceland, European Union (SC) prior to March 2024
  • 11 Mar 2024 Launched for Hyperlipoproteinaemia type II (In adolescents, In children) in USA (SC)
  • 11 Mar 2024 Regeneron Pharmaceuticals with Sanofi announces intention to submit regulatory application for Hyperlipoproteinaemia type II (In children) by mid 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top